See the DrugPatentWatch profile for ozempic

Based on the information available, Ozempic (generic name: semaglutide) is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes mellitus. It is administered subcutaneously, and the recommended dosage is 0.5 mg or 1 mg once weekly, depending on the patient's response and tolerability.

The dosage information is supported by the prescribing information provided by the Food and Drug Administration (FDA) and the drug manufacturer. It is essential to follow the healthcare provider's instructions regarding the dosage and administration of Ozempic.

In summary, the recommended dosage of Ozempic is either 0.5 mg or 1 mg once weekly, depending on the patient's response and tolerability.

Sources:

1. Ozempic (semaglutide) injection, for subcutaneous use [Prescribing Information]. FDA website. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209232s000lbl.pdf>. Accessed 2023-02-21.
2. Semaglutide. DrugPatentWatch.com website. <https://www.drugpatentwatch.com/drugs/semaglutide>. Accessed 2023-02-21.